Approximately 500 patients will be included in this patient registry. Data collection
includes demographics, clinical data of underlying disease and use of bisphosphonates,
denosumab and antiangiogenic drugs , degree and extension of osteonecrosis,
osteonecrosis-specific treatment, outcomes and complications within 1 year after treatment.